ABSTRACT - 599361 The disclosure relates to use of an undissolved form of lopinavir in the manufacture of a pharmaceutical dosage form for treating HIV/AIDS, wherein said dosage form is formulated for administration to a patient in need thereof without food, and said dosage form comprises lopinavir and ritonavir formulated in a solid solution or solid dispersion, and said solid solution or solid dispersion comprises copovidone and sorbitan monolaurate, and wherein said dosage form comprises from 50 to 85% by weight of copovidone, and from 2 to 20% by weight of sorbitan monolaurate, wherein said solid solution or solid dispersion is a solid solution.
